DK0975754T3 - Osteoprotegerin bindende proteiner og receptorer - Google Patents

Osteoprotegerin bindende proteiner og receptorer

Info

Publication number: DK0975754T3
Authority: DK; Denmark
Prior art keywords: fragments; encoding; sequence; nucleic acid; receptors
Prior art date: 1997-04-16

Application number

DK98918244T

Other languages

English (en)

Other versions

DK0975754T4 (da

Inventor

William J Boyle

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-16

Filing date

1998-04-15

Publication date

2007-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0975754(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-16 Priority claimed from US08/842,842 external-priority patent/US5843678A/en

1998-03-30 Priority claimed from US09/052,521 external-priority patent/US6316408B1/en

1998-04-15 Application filed by Amgen Inc filed Critical Amgen Inc

2007-10-01 Application granted granted Critical

2007-10-01 Publication of DK0975754T3 publication Critical patent/DK0975754T3/da

2016-03-21 Publication of DK0975754T4 publication Critical patent/DK0975754T4/da

Links

102000014914 Carrier Proteins Human genes 0.000 title abstract 2
108091008324 binding proteins Proteins 0.000 title abstract 2
102000008108 Osteoprotegerin Human genes 0.000 title 1
108010035042 Osteoprotegerin Proteins 0.000 title 1
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
239000012634 fragment Substances 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
208000020084 Bone disease Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
210000002997 osteoclast Anatomy 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK98918244.9T 1997-04-16 1998-04-15 Osteoprotegerin-bindende proteiner og deres receptorer DK0975754T4 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08/842,842 US5843678A (en)	1997-04-16	1997-04-16	Osteoprotegerin binding proteins
US88085597A	1997-06-23	1997-06-23
US09/052,521 US6316408B1 (en)	1997-04-16	1998-03-30	Methods of use for osetoprotegerin binding protein receptors
PCT/US1998/007584 WO1998046751A1 (en)	1997-04-16	1998-04-15	Osteoprotegerin binding proteins and receptors

Publications (2)

Publication Number	Publication Date
DK0975754T3 true DK0975754T3 (da)	2007-10-01
DK0975754T4 DK0975754T4 (da)	2016-03-21

Family

ID=27368158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98918244.9T DK0975754T4 (da)	1997-04-16	1998-04-15	Osteoprotegerin-bindende proteiner og deres receptorer

Country Status (27)

Country	Link
US (1)	US7923008B2 (da)
EP (2)	EP1717315A3 (da)
JP (2)	JP2001526532A (da)
CN (1)	CN1264427A (da)
AT (1)	ATE363533T1 (da)
AU (4)	AU743257B2 (da)
BG (1)	BG65242B1 (da)
BR (1)	BR9808545A (da)
CA (1)	CA2285746C (da)
CZ (1)	CZ302262B6 (da)
DE (1)	DE69837845T3 (da)
DK (1)	DK0975754T4 (da)
EA (1)	EA003636B1 (da)
EE (1)	EE05496B1 (da)
ES (1)	ES2284203T5 (da)
HU (1)	HU230547B1 (da)
ID (1)	ID23855A (da)
IL (1)	IL132304A0 (da)
NO (1)	NO325175B1 (da)
NZ (1)	NZ500253A (da)
PL (1)	PL190092B1 (da)
RO (1)	RO128635A2 (da)
SI (1)	SI0975754T2 (da)
SK (1)	SK288559B6 (da)
TR (1)	TR199902512T2 (da)
TW (1)	TW589376B (da)
WO (1)	WO1998046751A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
PT1114864E (pt) *	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
WO1999058674A2 (en) *	1998-05-14	1999-11-18	Immunex Corporation	Method of inhibiting osteoclast activity
ATE497001T1 (de)	1996-12-23	2011-02-15	Immunex Corp	Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja)	1997-04-15	2004-04-26	三共株式会社	新規蛋白質及びその製造方法
AU2008200700C1 (en) *	1997-04-15	2013-04-04	Daiichi Sankyo Co., Ltd	Novel Protein and Process for Producing The Same
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
EA003636B1 (ru)	1997-04-16	2003-08-28	Амген Инк.	Остеопротегеринсвязующие белки и рецепторы
WO2001060397A1 (en)	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20020106728A1 (en) *	2000-06-20	2002-08-08	Genentech, Inc.	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1541587A3 (en) *	1998-09-15	2007-06-20	Pharmexa A/S	Method for down-regulating osteoprotegerin ligand activity
HRP20010188A2 (en)	1998-09-15	2002-04-30	Pharmexa As	Method for down-regulating osteoprotegerin ligand activity
ATE348163T1 (de)	1998-10-23	2007-01-15	Amgen Inc	Thrombopoietin substitute
EP1194555B1 (en)	1999-06-28	2012-09-26	Genentech, Inc.	Methods for making apo-2 ligand using divalent metal ions
HK1043608B (en)	1999-08-17	2007-12-07	Biogen Ma Inc.	Baff receptor (bcma), an immunoregulatory agent
AU7615600A (en) *	1999-09-27	2001-04-30	Eli Lilly And Company	Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) *	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
WO2001062932A1 (en) *	2000-02-23	2001-08-30	Amgen Inc.	Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US6600018B1 (en)	2000-04-10	2003-07-29	The United States Of America As Represented By The Department Of Health And Human Services	Secreted frizzled related protein, sFRP, fragments and methods of use thereof
PT2857516T (pt)	2000-04-11	2017-08-28	Genentech Inc	Anticorpos multivalentes e utilizações dos mesmos
WO2002009755A2 (en)	2000-07-27	2002-02-07	Genentech, Inc.	Apo-2l receptor agonist and cpt-11 synergism
US20040247596A1 (en) *	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
AU9303001A (en)	2000-09-22	2002-04-02	Immunex Corp	Screening assays for agonists or antagonists of receptor activat or of nf-kb
JP4029041B2 (ja)	2001-01-10	2008-01-09	アメリカ合衆国	ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
TR201809678T4 (tr)	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
JP4509570B2 (ja)	2001-07-03	2010-07-21	ジェネンテック，インコーポレイテッド	ヒトｄｒ４抗体及びその使用法
EP2348043A1 (en)	2001-10-02	2011-07-27	Genentech, Inc.	APO-2 ligand variants and uses thereof
CA2466054C (en)	2001-11-13	2012-01-03	Genentech, Inc.	Apo-2 ligand/trail formulations
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
AU2003243139B2 (en)	2002-04-05	2007-06-21	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2011265413B2 (en) *	2002-04-05	2014-04-10	Amgen Inc.	Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
WO2004001009A2 (en)	2002-06-24	2003-12-31	Genentech, Inc.	Apo-2 ligand/trail variants and uses thereof
MXPA05006147A (es)	2002-12-10	2005-08-26	Schering Plough Ltd	Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
EP1773400A2 (en)	2004-07-08	2007-04-18	Amgen Inc.	Therapeutic peptides
CN101061238B (zh)	2004-08-06	2013-11-20	健泰科生物技术公司	使用生物标志的测定法和方法
ES2365719T3 (es)	2004-08-06	2011-10-10	Genentech, Inc.	Ensayos y procedimientos que utilizan biomarcadores.
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (pt)	2005-08-16	2018-05-22	Genentech Inc	método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
CA2629306A1 (en)	2005-11-23	2007-05-31	Genentech, Inc.	Methods and compositions related to b cell assays
US20090227032A1 (en)	2005-12-13	2009-09-10	Kyoto University	Nuclear reprogramming factor and induced pluripotent stem cells
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US8378084B2 (en) *	2006-12-22	2013-02-19	The Regents Of The University Of California	Fusion molecule based on novel TAA variant
MX2009012609A (es)	2007-05-22	2009-12-07	Amgen Inc	Composiciones y metodos para producir proteinas de fusion bioactivas.
JP2008307007A (ja)	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
HRP20140405T1 (hr) *	2007-06-20	2014-06-20	Galapagos N.V.	Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
JP5346925B2 (ja) *	2008-05-02	2013-11-20	国立大学法人京都大学	核初期化方法
EP2376120A2 (en)	2008-11-25	2011-10-19	Biogen Idec MA Inc.	Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
EP2434285A1 (en)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Breast cancer diagnostics
EP2433644A1 (en)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Breast cancer therapeutics
US9045403B2 (en)	2012-02-29	2015-06-02	Coyote Pharmaceuticals, Inc.	Geranyl geranyl acetone (GGA) derivatives and compositions thereof
US9119808B1 (en)	2012-10-08	2015-09-01	Coyote Pharmaceuticals, Inc.	Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
EP3712166A1 (en)	2013-09-05	2020-09-23	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015175861A1 (en)	2014-05-16	2015-11-19	Amgen Inc.	Assay for detecting th1 and th2 cell populations
WO2018138297A1 (en)	2017-01-27	2018-08-02	Kymab Limited	Anti-opg antibodies
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
CA3082728A1 (en)	2017-11-22	2019-05-31	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-maf status
US12325737B2 (en)	2018-03-26	2025-06-10	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
KR20220069982A (ko)	2019-09-26	2022-05-27	암젠 인크	항체 조성물의 생산 방법
EP4045515A4 (en)	2019-10-18	2023-10-18	The Regents Of The University Of Michigan	BIOMATERIAL SENSOR SYSTEMS
CN113621060B (zh) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	一种opg抗体对及其应用
WO2021247892A1 (en)	2020-06-04	2021-12-09	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en)	2020-10-15	2024-02-08	Amgen Inc.	Relative unpaired glycans in antibody production methods
AU2022289365A1 (en)	2021-06-07	2023-12-14	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja)	2021-10-05	2024-10-10	アムジエン・インコーポレーテツド	Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
JP2026516670A (ja)	2023-04-20	2026-05-26	アムジエン・インコーポレーテツド	相対的な不対グリカン含有量を決定する方法
AU2024325342A1 (en)	2023-08-14	2026-02-26	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2026090253A1 (en)	2024-10-23	2026-04-30	Amgen Inc.	Methods of determining glycan pairing content

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710457A (en)	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US6150090A (en) *	1986-01-09	2000-11-21	Massachusetts Institute Of Technology	Nuclear factors associated with transcriptional regulation
US5846534A (en)	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
WO1992009697A1 (en)	1990-11-30	1992-06-11	Celtrix Laboratories, Inc.	USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en)	1991-05-13	1992-11-14	Masahiko Sato	Method for inhibiting bone resorption
MX9204303A (es)	1991-07-23	1993-11-01	Rhone Poulenc Rorer Int	Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118119C (en)	1992-04-30	2001-07-31	Robert C. Thompson	Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5585479A (en)	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en)	1993-03-12	1996-11-26	Tam; Cherk S.	Method of increasing bone growth
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
JPH09502614A (ja)	1993-09-14	1997-03-18	メルクエンドカンパニーインコーポレーテッド	新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en)	1993-10-18	2001-07-31	Amgen Inc.	Tissue specific transgene expression
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
JP4046349B2 (ja) *	1994-11-07	2008-02-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子−γ
EP0727211A1 (en)	1995-02-10	1996-08-21	Smithkline Beecham Corporation	Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) *	1995-03-15	2003-09-04	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US7094564B1 (en)	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
WO1996028546A1 (en)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
WO1997000317A1 (en)	1995-06-07	1997-01-03	Osteosa Inc.	Osteoclast growth regulatory factor
AU6090896A (en)	1995-06-07	1997-01-15	Osteosa Inc.	Osteoclast growth regulatory factor
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
CA2225378C (en) *	1995-06-29	2012-04-17	Immunex Corporation	Cytokine that induces apoptosis
US6613544B1 (en)	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US5981220A (en) *	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
TW555765B (en) *	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja)	1996-08-19	1998-03-03	Snow Brand Milk Prod Co Ltd	新規ｄｎａ及びそれを用いた蛋白質の製造方法
PT1114864E (pt) *	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
FR2757507B1 (fr)	1996-12-20	1999-01-29	Inst Francais Du Petrole	Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
WO1998028423A2 (en)	1996-12-20	1998-07-02	Board Of Regents, The University Of Texas System	Compositions and methods of use for osteoclast inhibitory factors
ATE497001T1 (de) *	1996-12-23	2011-02-15	Immunex Corp	Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
WO1999058674A2 (en) *	1998-05-14	1999-11-18	Immunex Corporation	Method of inhibiting osteoclast activity
JP3523650B2 (ja)	1997-04-15	2004-04-26	三共株式会社	新規蛋白質及びその製造方法
US5843678A (en) *	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
EA003636B1 (ru)	1997-04-16	2003-08-28	Амген Инк.	Остеопротегеринсвязующие белки и рецепторы
CA2229449A1 (en) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use
AU7469998A (en)	1997-05-01	1998-11-24	Amgen, Inc.	Chimeric opg polypeptides
AU7705098A (en)	1997-05-29	1998-12-30	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like protein 8
US6087555A (en)	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US6790823B1 (en)	1998-04-23	2004-09-14	Amgen Inc.	Compositions and methods for the prevention and treatment of cardiovascular diseases
HRP20010188A2 (en) *	1998-09-15	2002-04-30	Pharmexa As	Method for down-regulating osteoprotegerin ligand activity
AU6078500A (en)	1999-07-09	2001-01-30	Amgen, Inc.	Combination therapy for conditions leading to bone loss
KR20010085996A (ko)	1999-09-03	2001-09-07	스티븐 엠. 오드레	암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
US20030144187A1 (en)	1999-09-03	2003-07-31	Colin R. Dunstan	Opg fusion protein compositions and methods
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en)	2000-02-23	2001-08-30	Amgen Inc.	Antagonistic selective binding agents of osteoprotegerin binding protein
US20040247596A1 (en)	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
AU9303001A (en) *	2000-09-22	2002-04-02	Immunex Corp	Screening assays for agonists or antagonists of receptor activat or of nf-kb
DE02726901T1 (de)	2001-05-17	2004-07-15	Immunex Corp., Seattle	Therapeutische verwendung von rang-antagonisten
MXPA03011270A (es) *	2001-06-06	2004-03-18	Immunex Corp	Uso de antagonistas rank para tratar cancer.
TR201809678T4 (tr)	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
US6753755B2 (en) *	2001-06-28	2004-06-22	Safer Home, Inc.	Electrical safety connector fuse
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) *	2001-12-18	2003-07-15	Kimberly-Clark Worldwide	Dispenser for sheet material containing a dispensing port incrementally variable within a range
AU2003243139B2 (en)	2002-04-05	2007-06-21	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7706431B2 (en) *	2005-06-30	2010-04-27	Nokia Corporation	System and method for providing optimized receiver architectures for combined pilot and data signal tracking

1998
- 1998-04-15 EA EA199900939A patent/EA003636B1/ru not_active IP Right Cessation
- 1998-04-15 HU HU0001400A patent/HU230547B1/hu unknown
- 1998-04-15 ES ES98918244.9T patent/ES2284203T5/es not_active Expired - Lifetime
- 1998-04-15 DE DE69837845.8T patent/DE69837845T3/de not_active Expired - Lifetime
- 1998-04-15 WO PCT/US1998/007584 patent/WO1998046751A1/en not_active Ceased
- 1998-04-15 CZ CZ0359899A patent/CZ302262B6/cs not_active IP Right Cessation
- 1998-04-15 IL IL13230498A patent/IL132304A0/xx unknown
- 1998-04-15 AT AT98918244T patent/ATE363533T1/de active
- 1998-04-15 BR BR9808545-0A patent/BR9808545A/pt not_active Application Discontinuation
- 1998-04-15 NZ NZ500253A patent/NZ500253A/xx not_active IP Right Cessation
- 1998-04-15 ID IDW991225A patent/ID23855A/id unknown
- 1998-04-15 EP EP06015956A patent/EP1717315A3/en not_active Withdrawn
- 1998-04-15 AU AU71205/98A patent/AU743257B2/en not_active Ceased
- 1998-04-15 DK DK98918244.9T patent/DK0975754T4/da active
- 1998-04-15 RO ROA201200577A patent/RO128635A2/ro unknown
- 1998-04-15 SI SI9830889T patent/SI0975754T2/sl unknown
- 1998-04-15 TR TR1999/02512T patent/TR199902512T2/xx unknown
- 1998-04-15 EP EP98918244.9A patent/EP0975754B2/en not_active Expired - Lifetime
- 1998-04-15 CA CA2285746A patent/CA2285746C/en not_active Expired - Lifetime
- 1998-04-15 SK SK1419-99A patent/SK288559B6/sk active Protection Beyond IP Right Term
- 1998-04-15 EE EEP199900611A patent/EE05496B1/xx unknown
- 1998-04-15 PL PL98336311A patent/PL190092B1/pl unknown
- 1998-04-15 JP JP54425798A patent/JP2001526532A/ja not_active Withdrawn
- 1998-04-15 CN CN98806073A patent/CN1264427A/zh active Pending
- 1998-04-16 TW TW087105837A patent/TW589376B/zh not_active IP Right Cessation
1999
- 1999-10-15 NO NO19995044A patent/NO325175B1/no not_active IP Right Cessation
- 1999-10-21 BG BG103824A patent/BG65242B1/bg unknown
2001
- 2001-11-30 AU AU95234/01A patent/AU779461C/en not_active Expired
2005
- 2005-04-27 AU AU2005201799A patent/AU2005201799B2/en not_active Expired
2006
- 2006-01-19 US US11/336,067 patent/US7923008B2/en not_active Expired - Fee Related
2007
- 2007-09-04 JP JP2007228804A patent/JP5001758B2/ja not_active Expired - Lifetime
2008
- 2008-06-05 AU AU2008202516A patent/AU2008202516A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0975754B2 (en)	2016-01-06
ATE363533T1 (de)	2007-06-15
EE9900611A (et)	2000-08-15
JP2001526532A (ja)	2001-12-18
SI0975754T1 (sl)	2007-10-31
AU2005201799A1 (en)	2005-05-26
AU779461C (en)	2005-10-13
NO995044D0 (no)	1999-10-15
BR9808545A (pt)	2000-05-23
WO1998046751A1 (en)	1998-10-22
ES2284203T5 (es)	2016-03-11
HUP0001400A2 (en)	2000-07-28
NO325175B1 (no)	2008-02-11
AU743257B2 (en)	2002-01-24
BG103824A (en)	2000-05-31
DK0975754T4 (da)	2016-03-21
SK141999A3 (en)	2000-05-16
DE69837845D1 (de)	2007-07-12
ID23855A (id)	2000-05-25
JP2008054682A (ja)	2008-03-13
EE05496B1 (et)	2011-12-15
NO995044L (no)	1999-12-15
US20060246064A1 (en)	2006-11-02
DE69837845T2 (de)	2008-01-31
HK1022330A1 (en)	2000-08-04
PL336311A1 (en)	2000-06-19
AU7120598A (en)	1998-11-11
RO128635A2 (ro)	2013-07-30
EP1717315A2 (en)	2006-11-02
NZ500253A (en)	2002-09-27
IL132304A0 (en)	2001-03-19
ES2284203T3 (es)	2007-11-01
BG65242B1 (bg)	2007-09-28
AU2005201799B2 (en)	2008-06-12
SK288559B6 (sk)	2018-05-02
US7923008B2 (en)	2011-04-12
EP0975754B1 (en)	2007-05-30
TR199902512T2 (xx)	2000-06-21
JP5001758B2 (ja)	2012-08-15
HU230547B1 (hu)	2016-11-28
EP1717315A3 (en)	2007-06-20
EP0975754A1 (en)	2000-02-02
CZ302262B6 (cs)	2011-01-19
TW589376B (en)	2004-06-01
DE69837845T3 (de)	2016-06-23
EA199900939A1 (ru)	2000-08-28
CA2285746A1 (en)	1998-10-22
PL190092B1 (pl)	2005-10-31
CA2285746C (en)	2010-09-28
AU779461B2 (en)	2005-01-27
SI0975754T2 (sl)	2016-04-29
EA003636B1 (ru)	2003-08-28
AU9523401A (en)	2002-01-24
AU2008202516A1 (en)	2008-06-26
CZ359899A3 (cs)	2000-02-16
HUP0001400A3 (en)	2001-12-28
CN1264427A (zh)	2000-08-23

Publication	Publication Date	Title
AU779461C (en)	2005-10-13	Osteoprotegerin binding proteins and receptors
NO961115D0 (no)	1996-03-19	Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
BR9814335A (pt)	2000-10-10	Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
ATE159429T1 (de)	1997-11-15	Methode zum überbringen von agenzien an zielzellen
DE69535641D1 (de)	2007-12-27	Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
EP2325316B8 (en)	2017-04-19	Novel hemopoietin receptor protein, NR10
EA200300381A1 (ru)	2003-10-30	Нуклеиновые кислоты и полипептиды нового рецептора
LU91759I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
EA199700143A1 (ru)	1997-12-30	Способ и композиция ждя липидизации гидрофильных молекул
PT2305715T (pt)	2017-03-02	Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
EE9800322A (et)	1999-04-15	TNF retseptoriga seotud faktori (TRAF) modulaatorid, nende valmistamine ja kasutamine
BR9407512A (pt)	1997-01-07	Sequência de ácidos nucléicos vírus recombinante defectivo vetor notadamente virale composição farmaceutica e utilização de uma sequencia de ácidos nucléicos
BR9508467A (pt)	1997-12-23	Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
HK1049017A1 (zh)	2003-04-25	人受体蛋白、相关的试剂和方法
ATE426028T1 (de)	2009-04-15	Zellvolumenregulierte humane kinase h-sgk
WO1997007135A3 (en)	1997-05-22	Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
EP0369816A3 (en)	1990-09-12	Monoclonal antibodies specific for human polymorphic epithelial mucin
WO1999063094A3 (en)	2000-04-13	Nucleotide and protein sequences of gpr1 and methods based thereon
WO1999019480A3 (en)	1999-06-24	Human receptor proteins; related reagents and methods
GEP20002244B (en)	2000-09-25	Osteoprotegerin